Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E23.21 EPS (ttm)2.74 Insider Own0.16% Shs Outstand1.64B Perf Week-2.17%
Market Cap104.56B Forward P/E19.97 EPS next Y3.19 Insider Trans-0.13% Shs Float1.64B Perf Month1.22%
Income4.59B PEG2.25 EPS next Q0.76 Inst Own70.30% Short Float0.57% Perf Quarter14.90%
Sales20.24B P/S5.17 EPS this Y184.60% Inst Trans0.05% Short Ratio1.52 Perf Half Y19.20%
Book/sh8.94 P/B7.13 EPS next Y6.94% ROA13.70% Target Price59.55 Perf Year27.27%
Cash/sh3.96 P/C16.07 EPS next 5Y10.34% ROE30.10% 52W Range46.01 - 66.10 Perf YTD9.00%
Dividend1.56 P/FCF72.11 EPS past 5Y4.20% ROI19.80% 52W High-3.63% Beta1.19
Dividend %2.45% Quick Ratio1.50 Sales past 5Y-1.80% Gross Margin73.50% 52W Low38.45% ATR0.93
Employees25000 Current Ratio1.60 Sales Q/Q5.60% Oper. Margin29.50% RSI (14)54.11 Volatility1.76% 1.34%
OptionableYes Debt/Eq0.56 EPS Q/Q-20.10% Profit Margin22.70% Rel Volume0.92 Prev Close64.18
ShortableYes LT Debt/Eq0.47 EarningsOct 26 BMO Payout55.80% Avg Volume6.08M Price63.70
Recom2.50 SMA20-0.55% SMA503.92% SMA20012.92% Volume5,595,017 Change-0.75%
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Oct-18-17 04:21PM  What to Expect from Big Pharmas After J&J's Solid Q3 Results? Zacks
09:12AM  Inside Bristol-Myers Squibbs Performance in 3Q17 Market Realist
09:10AM  Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : October 06th, 2017 (record date) : By the numbers : October 18, 2017 Capital Cube
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Oct-17-17 05:00PM  This hot trade is about to get even hotter: Trader CNBC Videos
03:56PM  US Pharma Mergers and Acquisitions in 3Q17 Market Realist
10:00AM  3 Dividend Healthcare Stocks Motley Fool
09:49AM  Bristol-Myers Gets Priority Review for Opdivo Label Expansion Zacks
Oct-16-17 04:15PM  U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibbs Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review Business Wire
10:44AM  What Goes Up.Is Bristol-Myers a $48 Stock?
09:23AM  Morning Movers: Nordstrom Tumbles, Adobe Drops, Bristol-Myers Slips
07:53AM  [$$] Bristol-Myers Gets a Boost
07:20AM  Corporate News Blog - Bristol-Myers Squibb's Opdivo to be Available for Head and Neck Cancer Patients in UK ACCESSWIRE
03:15AM  Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032 Business Wire
Oct-13-17 04:14PM  5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings Zacks
10:23AM  Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study Zacks
Oct-12-17 07:01PM  Cramer's lightning round: Zagg's got good swag CNBC Videos
09:00AM  Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH PR Newswire
Oct-09-17 11:34AM  The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September Motley Fool
10:35AM  Investors Are Scooping Up Shares of Apple, Ditching Bristol Myers and Pfizer
09:19AM  Is Bristol-Myers Squibb Companys (BMY) ROE Of 30.51% Sustainable? Simply Wall St.
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
06:59AM  Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine Business Wire
Oct-07-17 10:34AM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb Motley Fool
Oct-06-17 12:38PM  Missing Link: Long Capital One, Bristol-Myers CNBC Videos
12:26PM  Bristol-Myers Squibb Won't Be Left Behind in This Bull Market -- Jim Cramer
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Oct-05-17 10:37AM  The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September Motley Fool
Oct-04-17 05:38PM  Stillwater Investment Management, LLC Buys DowDuPont Inc, Bristol-Myers Squibb Company
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
06:59AM  Caregivers Wish Liver Cancer Received Greater Public Awareness in the U.S., New Survey Reveals Business Wire
Sep-29-17 10:40AM  Must-Know Changes to Bristol-Myers Squibbs Valuation Market Realist
09:11AM  Bristol-Myers Squibbs Immunoscience Products Market Realist
08:35AM  UNC lands $1.7M grant from Bristol-Myers Squibb American City Business Journals
07:40AM  Bristol-Myers Squibbs Cardiovascular Portfolio Market Realist
Sep-28-17 05:27PM  Tax reform could spark a wave of biopharma M&A CNBC Videos
01:36PM  Bulls dial into this stock CNBC Videos
10:41AM  Bristol-Myers Squibbs Virology Portfolio Market Realist
09:10AM  Bristol-Myers Squibbs Opdivo and Recent Developments Market Realist
07:42AM  Analyzing Bristol-Myers Squibbs Oncology Portfolio Market Realist
Sep-27-17 05:37PM  Bristol-Myers Squibbs Growing Quarterly Revenues Market Realist
05:00PM  Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer Business Wire
03:48PM  Bristol-Myers Squibbs Important Recent Developments Market Realist
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:37AM  What Happened to Allergans Valuation after 2Q17? Market Realist
Sep-26-17 12:51PM  Gilead Sciences: New Market, Same Problem?
10:24AM  Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal Zacks
08:25AM  Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues Zacks
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
06:52AM  Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs Zacks
Sep-25-17 10:49AM  Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer Zacks
08:35AM  Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer Zacks
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-22-17 06:10PM  Bristol-Myers Squibbs Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib Business Wire
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:00AM  AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors PR Newswire
06:59AM  AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors Business Wire
05:00AM  Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy Business Wire
Sep-21-17 08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
06:59AM  New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors Business Wire
06:59AM  Bristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference Business Wire
Sep-20-17 03:50PM  2 Important Dates for Big Pharma
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-18-17 10:19AM  Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear InvestorPlace
09:42AM  The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 Motley Fool
Sep-17-17 07:03AM  Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb Motley Fool
07:02AM  Bristol-Myers Squibb Stock Still a Beast?
Sep-16-17 10:47AM  Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? Motley Fool
Sep-15-17 11:41AM  Time to Adjust as Bristol-Myers Squibb Continues Its Climb
10:55AM  Oncology Space in Focus this Week on ESMO Presentations Zacks
09:34AM  Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE Zacks
06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
06:04AM  Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis? Motley Fool
Sep-14-17 04:20PM  This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche Investor's Business Daily
03:43PM  Halozyme to license drug delivery tech to Bristol-Myers a... CNBC Videos
03:19PM  Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale Motley Fool
11:45AM  Here's Why Halozyme Therapeutics, Inc. Is Soaring Today Motley Fool
08:00AM  Halozyme to license drug delivery tech to Roche, Bristol-Myers Reuters
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
08:00AM  Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take Forbes
07:18AM  Halozyme's stock soars after Bristol-Myers license deal MarketWatch
07:00AM  Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers
06:59AM  Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology Business Wire
Sep-13-17 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
04:15PM  Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors Business Wire
01:35PM  [$$] Bristol-Myers Stock May Be Fully Valued
Sep-12-17 05:36PM  Bristol-Myers Reports Positive Results from Melanoma Study Zacks
10:17AM  Company News For Sep 12, 2017 Zacks
08:00AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Sep-11-17 10:05AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
05:32AM  Cancer immunotherapy proves itself in earlier-stage disease Reuters
Sep-10-17 06:11PM  Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study Business Wire
06:05PM  After melanoma surgery, Bristol's Opdivo offers new care standard Reuters
01:00PM  Bristol's drug cocktail cuts kidney cancer death risk 37 pct Reuters
11:55AM  Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial Business Wire
11:55AM  Bristol kidney cancer drug cut death risk 37 pct in key patients Reuters
Sep-08-17 03:22PM  Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer Investor's Business Daily
10:34AM  2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August Motley Fool
10:21AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
09:45AM  Bristol-Myers' Opdivo Study Meets Early Success, Stock Up Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM